alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

30,580 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 376–400 of 483 studies published 2019 · free to read (page 16 of 20) · 30,580 in the whole library · How the 0–100 score works

Download bibliography of these 483 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 16,054 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Neuroinflammatory Processes, A1 Astrocyte Activation and Protein Aggregation in the Retina of Alzheimer's Disease Patients, Possible Biomarkers for Early Diagnosis

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Frontiers in neuroscience 2019-09-04

Alzheimer's disease (AD), a primary cause of dementia in the aging population, is characterized by extracellular amyloid-beta peptides aggregation, intracellular deposits of hyperphosphorylated tau, neurodegeneration and glial activation in the brain. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Salivary Biomarkers for Alzheimer's Disease and Related Disorders

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Neurology and therapy 2019-12-12

The search for accessible and cost-effective biomarkers to complement current cerebrospinal fluid (CSF) and imaging biomarkers in the accurate detection of Alzheimer disease (AD) and other common neurodegenerative disorders remains a challenging task. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Economic impacts of introducing diagnostics for mild cognitive impairment Alzheimer's disease patients

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Alzheimer's & dementia (New York, N. Y.) 2019-08-16

The budgetary impacts are not insignificant but are small in comparison to the likely market price of any disease-modifying treatments or to the probable costs of missed or inaccurate diagnosis. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Early-onset Alzheimer Disease and Its Variants

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Continuum (Minneapolis, Minn.) 2019-02-01

Neuroimaging features of early-onset AD in comparison to late-onset AD include greater frequency of hippocampal sparing and posterior neocortical atrophy, increased tau burden, and greater connectomic changes affecting frontoparietal networks rather than the default mode network. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Late-onset Alzheimer Disease

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Continuum (Minneapolis, Minn.) 2019-02-01

Vascular risk factors, sleep disorders, and traumatic brain injury are associated with an increased risk of AD, while increased cognitive and physical activity throughout the lifespan reduce the risk of disease. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Dynamic 11C-PiB PET Shows Cerebrospinal Fluid Flow Alterations in Alzheimer Disease and Multiple Sclerosis

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2019-03-08

ANOVA revealed significant group differences in lateral ventricular SUVR across the Alzheimer, mild cognitive impairment, and healthy control groups ( P = 0.004). 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Companion robots for older people: importance of user-centred design demonstrated through observations and focus groups comparing preferences of older people and roboticists in South West England

✓ Peer-reviewed alzhub usefulness score 46 out of 100. BMJ open 2019-09-26

The observed misalignment of opinion between end users and developers on desirable design features of companion robots demonstrates the need for user-centred design during development. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Identifying incident dementia by applying machine learning to a very large administrative claims dataset

✓ Peer-reviewed alzhub usefulness score 46 out of 100. PloS one 2019-07-05

Alzheimer's disease and related dementias (ADRD) are highly prevalent conditions, and prior efforts to develop predictive models have relied on demographic and clinical risk factors using traditional logistical regression methods. 5 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Language Performance of Individuals at Risk for Mild Cognitive Impairment

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Journal of speech, language, and hearing research : JSLHR 2019-03-01

Language performance deficits can appear early before impairment in episodic memory, visuospatial construction ability, or mental status in individuals at risk for MCI. 5 key findings →

Participants: 86 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Machine Learning-Based Framework for Differential Diagnosis Between Vascular Dementia and Alzheimer's Disease Using Structural MRI Features

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Frontiers in neurology 2019-10-25

The experimental results demonstrate that the SVM with RBF achieved an encouraging performance with sensitivity (SEN), specificity (SPE), and accuracy (ACC) values of 82.65%, 87.17%, and 84.35%, respectively (AUC = 0.861, 95% CI = 0.820-0.902), for the differential diagnosis between VaD and AD. 2 key findings →

Participants: 93 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Distinct Signaling Pathways Regulate TREM2 Phagocytic and NFκB Antagonistic Activities

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Frontiers in cellular neuroscience 2019-10-10

Several genetic variants of the Triggering Receptor Expressed on Myeloid Cells-2 (TREM2) have been shown to increase the risk of developing Alzheimer's disease (AD) supporting a role of microglia and immune cells in the pathobiology of AD. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Analysis of 50 Neurodegenerative Genes in Clinically Diagnosed Early-Onset Alzheimer's Disease

✓ Peer-reviewed alzhub usefulness score 46 out of 100. International journal of molecular sciences 2019-03-26

Alzheimer's disease (AD), Parkinson's disease (PD), frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), and prion diseases have a certain degree of clinical, pathological, and molecular overlapping. 4 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Elevated cerebrospinal fluid total tau in former professional athletes with multiple concussions

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Neurology 2019-05-08

Concentrations of phosphorylated tau181, total tau (t-tau), and β-amyloid in the CSF were measured in 3 groups: 22 former professional athletes with multiple concussions (mean ± SD age 55.9 ± 12.2 years), 5 healthy controls (age 57.4 ± 5.2 years), and 12 participants (age 60.0 ± 6.6 years) diagnosed with Alzheimer disease (AD). 4 key findings →

Participants: 12 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Linking Molecular Pathways and Large-Scale Computational Modeling to Assess Candidate Disease Mechanisms and Pharmacodynamics in Alzheimer's Disease

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Frontiers in computational neuroscience 2019-08-13

In this work, we demonstrate how computational multi-scale brain modeling links phenomena of different scales and therefore identifies potential disease mechanisms leading the way to improved diagnostics and treatment. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

ApoE (Apolipoprotein E) in Brain Pericytes Regulates Endothelial Function in an Isoform-Dependent Manner by Modulating Basement Membrane Components

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Arteriosclerosis, thrombosis, and vascular biology 2019-10-31

ApoE4 impairs pericyte-mediated basement membrane formation, potentially contributing to the cerebrovascular effects of apoE4. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Tau PET imaging with 18F-PI-2620 in Patients with Alzheimer Disease and Healthy Controls: A First-in-Humans Study

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2019-11-11

18 F-PI-2620 showed peak brain uptake around 5 min after injection and fast washout from nontarget regions. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 30,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,580 records, built mostly from automated pulls of Europe PMC (64.7% of the library) and OpenAlex (16.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,037 records (3.4% of the library) are not peer-reviewed — 964 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events